Ucb Eulerpool naujienos

Ucb Eulerpool News

Ucb akcijų naujienos

Ucb stebi daugybė žurnalistų ir investuotojų visame pasaulyje. Naujausias Ucb naujienas mes pateikiame čia.

• rugsėjo 30 d. ·

  Yahoo
  UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
• rugsėjo 30 d. ·

  TipRanks
  Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
• rugsėjo 27 d. ·

  Yahoo
  UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
• rugsėjo 25 d. ·

  Yahoo
  UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
• rugsėjo 24 d. ·

  Yahoo
  Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
• rugsėjo 24 d. ·

  Seeking Alpha
  Biogen, UCB mark late-stage trial win for autoimmune disease therapy
• rugsėjo 24 d. ·

  Yahoo
  UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
• rugsėjo 23 d. ·

  Yahoo
  UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
• rugsėjo 23 d. ·

  Seeking Alpha
  UCB gets expanded FDA approval for psoriasis drug Bimzelx
• rugsėjo 16 d. ·

  TipRanks
  Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)